Category: Statistics

Insect Sci. 2025 Jul 22. doi: 10.1111/1744-7917.70123. Online ahead of print.

ABSTRACT

Galleria mellonella is becoming increasingly used as a model organism for studying human pathogen infection disease. Therefore, all factors affecting the level of immune response of G. mellonella should be evaluated. One of these factors is DNA methylation, among the most important epigenetic modifications. Firstly, we investigated the presence of CpG dinucleotides and their methylation status of eggs, last instars, pupae, and adults using HpaII, MspI, and ScrFI methylation-sensitive restriction endonucleases. The gel analysis of the restriction pattern of HpaII, MspI, ScrFI, and MspI+ScrFI on G. mellonella genomic DNA showed that all enzymes produced a wide range of smears. The digestion of DNA samples of egg, pupa, and adult resulted in a smear at higher molecular weight for MspI+ScrFI, and these differences were statistically significant. These results confirm the presence of CpG dinucleotides and methylation at the internal and outer cytosines in different developmental stages of G. mellonella. Presence of global DNA methylation, which was by 3%-5% was investigated in various developmental stages of G. mellonella. Then, different levels of DNA methylation in the last instars of G. mellonella were created with the hypomethylation agent, zebularine (0.25-32 mg/mL), and immunity responses were examined. The most effective doses of zebularine, to create a global hypomethylation status in G. mellonella larvae, were 0.25 and 1 mg/mL. The humoral/cellular immune response of G. mellonella larvae became weak at high hypomethylation. These results present the level of DNA methylation during all developmental stages of G. mellonella and how zebularine treatment affects physiological processes.

PMID:40693385 | DOI:10.1111/1744-7917.70123

J Feline Med Surg. 2025 Jul;27(7):1098612X251338174. doi: 10.1177/1098612X251338174. Epub 2025 Jul 22.

ABSTRACT

ObjectivesThis study aimed to develop a quantitative scoring method for the evaluation of mucosal fibrosis (MF) and assess its correlation with World Small Animal Veterinary Association scores, clinical abnormalities, disease severity, diagnosis and outcome in cats with lymphoplasmacytic enteritis (LPE) or low-grade intestinal T-cell lymphoma (LGITL).MethodsFormalin-fixed, paraffin-embedded small intestinal biopsy specimens from 13 cats with LPE and 14 cats with LGITL were included. MF was quantitatively measured in three separate areas (villi, apical crypts [ACs] and basal crypts) using an image processing program. The fractional fibrotic area (%FFA) was calculated based on the mean fibrosis scores in five representative fields. MF was also scored by a single board-certified pathologist on sequential slides stained with either hematoxylin and eosin (H&E) or Masson’s trichrome (MT) on a four-point scale in the areas described above. Statistical analysis was performed to assess the correlation between clinical and pathological variables, diagnosis and outcome.ResultsThe %FFA scores correlated well with fibrosis scores on MT stains (r = 0.52, P = 0.01) but did not correlate with H&E stains (r = 0.29, P = 0.14). The %FFA in the villi and AC area was negatively correlated with a modified Feline Chronic Enteropathy Activity Index in cats with LGITL (r = -0.57, P = 0.04). A histopathologic diagnosis of LPE showed a weak correlation with MF in the AC area (r = 0.38, P = 0.05). The survival time of cats with chronic enteropathy (CE) was weakly negatively correlated with MF (r = -0.38, P = 0.05).Conclusions and relevanceMF is more effectively assessed using MT staining compared with H&E staining alone. Increased MF in the AC region may indicate a diagnosis of LPE. Although increased MF did not correlate with increased disease activity, it appears to be a negative prognostic factor for survival in cats with CE.

PMID:40693384 | DOI:10.1177/1098612X251338174

Diabetes Obes Metab. 2025 Jul 22. doi: 10.1111/dom.16588. Online ahead of print.

ABSTRACT

AIMS: Diabetes is increasingly reported as a cause of blindness and vision loss. However, the trends in the burden of blindness and vision loss attributed to diabetic retinopathy (DR) have yet to be fully elucidated.

MATERIALS AND METHODS: Utilizing the latest data from the Global Burden of Disease Study 2021, we extracted prevalence and years lived with disability (YLD) data for these conditions, including their respective age-standardized rate (ASR) indicators. The data were categorized by time, location, age and sociodemographic index (SDI). This study conducted comprehensive analyses over a span of 32 years (1990-2021) to identify trends in blindness and vision loss attributed to DR, employing advanced statistical methods such as estimated annual percentage change (EAPC), health inequity analysis (slope index and concentration index), decomposition analysis, frontier analysis, and predictive modelling using the Bayesian age-period-cohort method.

RESULTS: From 1990 to 2021, the global burden of blindness and vision loss attributed to DR (measured by prevalence and YLD) increased rapidly, and this trend was projected to remain stable until 2046. The age-standardized prevalence rates (ASPR) and age-standardized YLD rates (ADYR) in all five SDI regions exhibited an upward trend. Notably, the high and high-middle SDI regions surpassed global levels, with their EAPC and 95% CI values all greater than 0. In 2021, the prevalence cases, YLD cases, prevalence rates and YLD rates for females across all age groups were generally higher than those for males, and were approximately 1.4 times those of males. Health inequality analysis indicates that over the past 32 years, there have been significant disparities in the distribution of prevalence rates and YLD rates associated with the SDI across 204 countries and regions. Decomposition analysis on a global and cross-SDI regional scale indicated that ageing, population growth and epidemiological changes had all increased the burden of prevalence and YLD. The frontier analysis showed that high SDI regions had greater potential for improvement. In 2021, compared with the relatively stable trend of type 1 diabetes, the prevalence and YLD rates of blindness and vision loss attributable to type 2 diabetes rapidly increased with age.

CONCLUSIONS: Blindness and vision loss attributed to DR pose significant global health and economic challenges. It is imperative for health system managers to formulate strong strategies to address these growing issues effectively.

PMID:40693378 | DOI:10.1111/dom.16588

Int J Gynaecol Obstet. 2025 Jul 22. doi: 10.1002/ijgo.70403. Online ahead of print.

ABSTRACT

OBJECTIVE: To compare the effectiveness of two dosages (12.5 and 25 μg) of 17β-estradiol vaginal gel for treating postmenopausal vaginal atrophy.

METHODS: A randomized non-inferiority trial was conducted in the Gynecologic Endocrinology and Menopause Clinic of a university hospital from June 2022 to February 2023. A total of 80 postmenopausal women were randomly assigned to receive a 12.5 μg (half-dose) or 25 μg (full-dose) 17β-estradiol vaginal gel daily for 14 days, followed by twice-weekly for 10 weeks. Efficacy outcomes were vaginal maturation value (VMV), vaginal health index (VHI), vaginal pH, most bothersome symptoms (MBSs), and female sexual function index (FSFI). Safety outcomes were endometrial thickness, serum estradiol level, and adverse events. All study outcomes were evaluated at three time points: baseline, week 4, and week 12.

RESULTS: At week 12, both the half-dose and full-dose groups displayed a significant improvement in the VMV, with median (25th-75th percentile) of 67.3 (59.1-72.9) and 71.8 (60.3-79.5), respectively. While the full-dose group exhibited slightly greater improvement in VMV, the difference was not statistically significant. The upper bound of the 95% confidence interval (CI) for the median difference in VMV was below the predefined non-inferiority margin of 15 (4.5, 95% CI: -0.5, 10.0; P = 0.082). Additionally, both groups demonstrated significant improvements from baseline in all efficacy outcomes without any safety concerns.

CONCLUSION: Both 12.5 and 25 μg doses of 17β-estradiol vaginal gel are safe and effectively improve vaginal atrophy in postmenopausal women. The non-inferiority of the half-dose to the full-dose suggests its potential as a cost-effective treatment option with comparable benefits.

PMID:40693355 | DOI:10.1002/ijgo.70403

J Diabetes. 2025 Jul;17(7):e70106. doi: 10.1111/1753-0407.70106.

ABSTRACT

Glucose-lowering medication expenditures per user by different payers among patients with diabetes.

PMID:40693336 | DOI:10.1111/1753-0407.70106

Catheter Cardiovasc Interv. 2025 Jul 22. doi: 10.1002/ccd.70040. Online ahead of print.

ABSTRACT

AIMS: We aimed to externally validate the PRECISE-DAPT cancer score which showed better accuracy in predicting bleeding events in patients with cancer than the original PRECISE-DAPT score.

METHODS: We used data from the BleeMACS (Bleeding complications in a Multicenter registry of patients discharged after an Acute Coronary Syndrome) project. We compared the performance and clinical usefulness of the original score and the cancer score by calculating the C-statistic, the net reclassification index (NRI), and decision curve analysis.

RESULTS: A total of 13,932 patients were included, of which 864 patients had a diagnosis of cancer at the time of presentation with an AMI. According to the original PRECISE DAPT score, 63.3% of patients with cancer were classified as HBR, whereas 94.9% of patients with cancer were classified as HBR according to the cancer score. Cox-regression models showed that patients classified as HBR by the updated cancer score have higher odds of bleeding (HR 2.6, 95% CI 2.1-3.1) events than patients classified as HBR by the original score (HR 2.2, 95% CI 1.8-2.7). The cancer score showed higher discrimination ability (C-statistic 0.66) than the original score (C-statistic 0.64). The overall NRI of the cancer score was 2.7%. The decision curves analysis showed that the cancer score use is roughly identical to the original score in patients without cancer but superior to the original score in patients with cancer.

CONCLUSION: The PRECISE-DAPT cancer score is a valid and useful tool for the prediction of bleeding risk in patients with cancer and presenting with AMI.

PMID:40693319 | DOI:10.1002/ccd.70040

BJOG. 2025 Jul 22. doi: 10.1111/1471-0528.18319. Online ahead of print.

ABSTRACT

B. Haydardedeoglu, F. Gjemalaj, P.C. Aytac, and E.B. Killicdag, “Direct Aspiration Versus Follicular Flushing in Poor Responders Undergoing Intracytoplasmic Sperm Injection: A Randomised Controlled Trial,” BJOG: An International Journal of Obstetrics & Gynaecology 124, no. 8 (2017): 1190-1196, https://doi.org/10.1111/1471-0528.14629. The above article, published online on 09 March 2017 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Aris Papageorghiou; and John Wiley & Sons Ltd. UK. Concerns were raised by a third party regarding the randomized control trial and the successful implementation of randomization. The third party was unable to recalculate the statistical results presented in Table 1, raising concerns that the statistical reports were also flawed. The authors provided their raw dataset to the journal so it could be evaluated by an independent expert. This expert confirmed that many of the statistical results were not reproducible using the reported methods. They also found several inconsistencies and errors within the article, including the duplication of two participants in the dataset. As a result, the data and conclusions are considered unreliable and the article must be retracted.

PMID:40693313 | DOI:10.1111/1471-0528.18319

BJOG. 2025 Jul 22. doi: 10.1111/1471-0528.18318. Online ahead of print.

ABSTRACT

M. El-Sedeek, E.E. Awad, S.M. Elsebaey, “Evaluation of Postpartum Blood Loss After Misoprostol-Induced Labour,” BJOG: An International Journal of Obstetrics and Gynaecology, 116, 3 (2009): 431-435, https://doi.org/10.1111/j.1471-0528.2008.02054.x. The above article, published online on 21 January 2009 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Aris Papageorghiou; and John Wiley & Sons Ltd. UK. Concerns were raised by a third party regarding the statistical data reported in the article. The third party noted the p-values reported in Table 1 were not compatible with the article’s summary data, and the distribution data featured in the scatterplots of Figures 3 and 4 was unusual. An independent expert evaluated the summary data reported in the article and confirmed that many of the statistical results were not reproducible using reported methods. The expert noted that there were several instances of data anomalies within the article, including the distribution of postpartum bleeding within Group 1, where the scores reported feature a pattern that is unusual. The authors did not respond when asked for their original data and clarification. As a result, the data and conclusions are considered unreliable, and the article must be retracted.

PMID:40693309 | DOI:10.1111/1471-0528.18318

BJOG. 2025 Jul 22. doi: 10.1111/1471-0528.18317. Online ahead of print.

ABSTRACT

M. El-Sedeek, A.A. Korish, and M.M. Deef, “Plasma Orexin-A Levels in Postmenopausal Women: Possible Interaction With Estrogen And Correlation With Cardiovascular Risk Status,” BJOG: An International Journal of Obstetrics and Gynaecology 117, no. 4 (2010): 488-492, https://doi.org/10.1111/j.1471-0528.2009.02474.x. The above article, published online on 08 February 2010 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Aris Papageorghiou; and John Wiley & Sons Ltd. UK. Concerns were raised by a third party regarding the reported calculations and statistical results. The third party was unable to recalculate the mean BMI using the reported weight and height metrics and also noted that the F values in Tables 1 and 2 were unusually large and the p-values reported in these tables do not appear compatible with the reported summary data. An independent expert evaluated the summary data reported in the article and confirmed the incompatibility of the statistical results and found that both the reported and recalculated F values are implausibly large. The authors did not respond when asked for their original data and clarification. As a result, the data and conclusions are considered unreliable, and the article must be retracted.

PMID:40693303 | DOI:10.1111/1471-0528.18317

Clin Ophthalmol. 2025 Jul 17;19:2373-2381. doi: 10.2147/OPTH.S519777. eCollection 2025.

ABSTRACT

PURPOSE: To compare the efficacy, safety and outcomes of micropulse cyclophotocoagulation (MP-CPC) to ultrasound cycloplasty (UCP) in patients referred to a tertiary eye care center in Riyadh, Saudi Arabia.

PATIENTS AND METHODS: A retrospective study evaluated data from patients who had undergone MP-CPC or UCP from January 2017 to October 2023. Patients who lost to follow up and patients with incomplete medical reports were excluded from the study. Data was collected for day 1, 2nd week, 1 month and 3, 6, and 12 months postoperatively. At each visit, data was collected on intraocular pressure (IOP), corrected distance visual acuity (CDVA), medications and possible complications. Data was compared between groups. P<0.05 was considered statistically significant.

RESULTS: Out of 139 eyes, 65 underwent UCP, and 74 underwent MP-CPC. IOP in the UCP group decreased from 29.67±9.82 mmHg preoperatively to 21.00±6.78 mmHg at one year postoperatively and in the MP-CPC group, IOP decreased from 28.44±9.46 mmHg to 20.41±8.77 mmHg respectively. In the UCP group, at the 1-year follow-up, vision remained unchanged from the preoperative levels in 6 eyes (27.3%), while 2 eyes (9.1%) lost 1 line of vision, and 8 eyes (36.4%) experienced a loss of ≥2 lines. In the MP-CPC group, at the 1-year follow-up, vision remained unchanged in 24 eyes (43.6%), 2 eyes (3.6%) lost 1 line, and 20 eyes (36.4%) had a loss of ≥2 lines. The number of antiglaucoma medications at 1 year postoperatively did not differ between groups. The qualified success rate at 1 year was similar between groups.

CONCLUSION: Both UCP and MP-CPC are safe and effective for reducing IOP in refractory glaucoma, with similar reductions observed between the two techniques. Visual outcomes and qualified success rates were comparable between UCP and MP-CPC.

PMID:40693283 | PMC:PMC12278948 | DOI:10.2147/OPTH.S519777